Future efforts should focus on establishing standardized immunohistochemical (IHC) assays for PELI1 detection using tumor tissue microarrays and evaluating its diagnostic and prognostic utility in a real-world clinical setting, ideally in combination with established biomarkers to assess its additive value. The gene discussed is PELI1; the disease is neoplasm.